Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Myriad GeneticsLTS:0K3W -43.78%54 Median PS Value is $20.48 as of Aug. 01, 2026, which is 2957% above its 10-year median of 0.67. GuruFocus rates LTS:0K3W with a GF Score™ of 54/100 and a GF Value™ of $15.41 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 88 Medical Diagnostics & Research companies, Myriad Genetics ranks better than 87.5% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
As of today (2026-08-01), Myriad Genetics's share price is $2.90. Myriad Genetics's Median PS Value is $20.48. Therefore, Myriad Genetics's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for Myriad Genetics's Median PS Value or its related term are showing as below:
During the past 13 years, the highest Price to Median PS Value of Myriad Genetics was 1.14. The lowest was 0.21. And the median was 0.67.
LTS:0K3W's Price-to-Median-PS-Value is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 0.9 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
Myriad Genetics (LTS:0K3W) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Myriad Genetics's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
2.90
/
20.48
=
0.14
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Myriad Genetics Median PS Value Related Terms
Myriad Genetics Median PS Value Historical Data
* Premium members only.
The historical data trend for Myriad Genetics's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0K3W vs FLGT, CSTL, BDSX: Median PS Value Comparison
For the Diagnostics & Research subindustry, Myriad Genetics's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Myriad Genetics Price-to-Median-PS-Value vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Myriad Genetics's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 2.3803.
Myriad Genetics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $8.604.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Myriad Genetics (LTS:0K3W) has a Median PS Value of $20.48 as of Aug. 01, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Myriad Genetics and its competitors. This is 2957% above median its historical median of 0.67. Over the past decade, Myriad Genetics' Median PS Value has ranged from 0.21 to 1.14. According to the industry distribution chart, Myriad Genetics ranks #11 out of 88 companies in the Medical Diagnostics & Research industry, placing it in the top 12.5%.
Is Myriad Genetics' Median PS Value too high?
Myriad Genetics' current Median PS Value of $20.48 is 2957% above median its 10-year median of 0.67. Over the past 10 years, this metric has ranged from a low of 0.21 to a high of 1.14. The Medical Diagnostics & Research industry median Median PS Value is 0.90. Myriad Genetics' value of $20.48 is 2175.6% above this industry median. Based on the distribution chart, Myriad Genetics ranks #11 out of 88 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Myriad Genetics has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Myriad Genetics' Median PS Value compare to FLGT and CSTL?
According to the Medical Diagnostics & Research industry distribution chart, Myriad Genetics ranks #11 out of 88 companies for Median PS Value. This places Myriad Genetics in the top 13% of its industry — outperforming the majority of peers. The industry median Median PS Value is 0.90. Myriad Genetics' value of $20.48 is 2175.6% above this benchmark. Historically, Myriad Genetics' own Median PS Value has ranged from 0.21 to 1.14 over the past decade. While the company's 10-year median is 0.67 vs. the industry median of 0.90, Myriad Genetics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Medical Diagnostics & Research company?
The median Median PS Value among Medical Diagnostics & Research companies is 0.90, based on 88 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Myriad Genetics's current Median PS Value of $20.48 is 2175.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Myriad Genetics and its competitors. For the Medical Diagnostics & Research industry, the median Median PS Value is 0.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Myriad Genetics's current Median PS Value is $20.48, which is 2957% above median its own 10-year median of 0.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Myriad Genetics stock overvalued right now?
Based on GuruFocus' analysis, Myriad Genetics (LTS:0K3W) is currently considered Possible Value Trap. The stock's GF Value™ is $15.41, compared to a current price of $2.90 — trading 81.2% below its estimated fair value. The current Median PS Value is $20.48, which is 2957% above median its 10-year median of 0.67 and 2175.6% above the Medical Diagnostics & Research industry median of 0.90. Myriad Genetics' overall GF Score™ is 54/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Myriad Genetics (LTS:0K3W), the current Median PS Value is $20.48 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Myriad Genetics (LTS:0K3W) Overvalued in 2026?
Based on GuruFocus' analysis, Myriad Genetics stock appears to be undervalued.
The current stock price of $2.90 is trading 81.2% below its estimated GF Value™ of $15.41.
GuruFocus considers Myriad Genetics to be Possible Value Trap.
Key valuation signals for LTS:0K3W:
Median PS Value: $20.48 (2957% above median its 10-year median of 0.67)
GF Value™: $15.41 vs. price of $2.90 (81.2% below fair value)
Industry Position: 2175.6% above the Medical Diagnostics & Research median (#11 of 88)
No single metric tells the full story. See the LTS:0K3W stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
54GF Score
Get the complete analysis for LTS:0K3W
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0K3W has been successfully added to your 
